NYSE:JNJ 16 September 2025 - 1 December 2025

As of December 1, 2025. This article is for information only and is not investment advice. Johnson & Johnson stock is trading close to its 52‑week high around the low‑$200s per share, giving the healthcare giant a market capitalization of roughly $500–505 billion.PortfoliosLab+1

Johnson & Johnson heads into the new trading week sitting just under all‑time highs, after a powerful rally that’s pushed the healthcare giant toward a $500 billion market value.FinancialContent+1 With U.S. markets reopening on Monday, December 1, 2025, investors watching the premarket tape will be weighing three things:

Updated: November 30, 2025 Johnson & Johnson stock has quietly turned into one of 2025’s big winners. After years of trading like a sleepy defensive name, JNJ has gone on an 11‑ to 13‑day winning streak, pushed its market capitalization to roughly $500 billion, and logged one of its strongest years since the mid‑1990s. Nai500

Johnson & Johnson is quietly turning into one of 2025’s standout mega‑cap stories. By this afternoon on Wednesday, November 26, J&J shares were trading around $207 per share, up modestly on the day and hovering near their all‑time highs.Macrotrends That price puts the healthcare giant’s market value just under the $500 billion mark, a level the stock briefly crossed this week as it touched intraday highs around $207.7.Bloomberg Law+1 It also caps a powerful multi‑week run driven by strong Q3 earnings, new drug data, dealmaking and a wave of positive analyst and institutional attention.

Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex and its autoimmune blockbusters driving growthts2.techreuters.com. Adjusted EPS of $2.80 beat forecasts, and management raised full-year 2025 product revenue guidance to $93.5–93.9Breuters.com. Such beats and raises were well-received: on Oct. 14 JNJ stock spiked ~2%, closing near $191ts2.tech. Analysts point out that JNJ now expects 2026 sales growth above 5%, reflecting confidence in its new drug launches and MedTech momentumts2.techinvesting.com. Even as the blockbuster Stelara loses exclusivity, JP Morgan calls J&J “one of the cleaner stories” in big pharma, given steady core growthreuters.com. A major strategic shift is underway: J&J will spin off its orthopedics unit into a standalone named DePuy Synthests2.tech. This follows the 2023 consumer health split and is aimed at “unlocking value,” as the business generates about 10% of JNJ’s revenue. Management says the move lets each company focus on its strengths – e.g. J&J doubling down on cancer, immunology, robotics and next-gen surgeryts2.techts2.tech. Experts agree this could sharpen J&J’s margins: SeekingAlpha’s news team notes the spin-off “aims to focus J&J on higher-growth, higher-margin markets,” potentially boosting agilityts2.tech. In fact, TS2.Tech